Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled
Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral sclerosis (ALS). Prilenia’s oral therapy pridopidine was selected as the trial’s fourth regimen (NCT04615923), with…